Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Apogee Therapeutics, Inc.NASDAQ: APGE

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q2 FY2026 stock-based compensation of $16.66M rose 46.9% year over year, behind the +60.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at +178.5% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +46.9% toward the trailing-twelve-month pace of +60.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$16.66M-2.9% QoQ
Last fiscal yearDec 2025
$46.28M+98.3% YoY
LTMJun 2026
$57.63M+60.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.9%——
1 year+98.3%——
3-year CAGR+178.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
46.28M USD
Year-over-year change
+98.3%
3-year CAGR
+178.5%

Stock-Based Compensation vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +60.4% is the 3rd highest of 10, against a peer median of +1.1%.
  • Over three fiscal years its annual growth of +178.5% compares with a peer median of +22.8%.
APGE Competitors
Stock-Based Compensation for APGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$142.83M USD-11.3%+5.5%21.3%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$64.29M USD+20.9%+38.1%—
ZLABZai Lab LimitedLTM Jun 2026$58.29M USD-12.7%+2.3%13.0%
APGEApogee Therapeutics, Inc.LTM Jun 2026$57.63M USD+60.4%+178.5%—
IRONDisc Medicine, Inc.LTM Sep 2026$50.54M USD+76.5%+154.3%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$36.45M USD+48.9%+240.5%591.2%
CNTACentessa Pharmaceuticals plcLTM Mar 2026$33.64M USD+1.1%+7.4%—
CELCCelcuity Inc.LTM Jun 2026$28.46M USD+203.0%+66.4%—
AAPGAscentage Pharma Group InternationalFY2025CN¥20.87M CNY-0.2%-1.9%3.7%
LEGNLegend Biotech CorporationLTM Sep 2026$7.7M USD-87.8%—0.6%
Peer median (excluding APGE) —+1.1%+22.8%13.0%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.79M)(83.99M)(182.15M)(255.84M)
Depreciation & Amortization00189K1.42M
Deferred Income Tax0000
Stock-Based Compensation2.14M6.1M23.33M46.28M
Change in Working Capital9.82M6.11M(2M)(15.48M)
Accounts Receivables0000
Inventory0000
Accounts Payables418K1.61M(1.07M)150K
Other Working Capital9.4M4.49M(930K)(15.63M)
Other Non-Cash Items11.4M(2.98M)(10.55M)(3.82M)
Operating Cash Flow(16.43M)(74.76M)(171.17M)(227.45M)
Capital Expenditures0(167K)(1.15M)(5.15M)
Acquisitions (Net)0000
Purchases of Investments0(303.74M)(649.45M)(642.3M)
Sales of Investments030M350.14M467.87M
Other Investing Activities0000
Investing Cash Flow0(273.91M)(300.46M)(179.57M)
Debt Repayment0000
Common Stock Issued168.32M315.39M493.48M396.49M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities001.63M0
Financing Cash Flow168.32M315.39M495.11M396.49M
Effect of Forex Changes0000
Net Change in Cash151.89M(33.28M)23.47M(10.53M)
Free Cash Flow(16.43M)(74.93M)(172.33M)(232.6M)

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.